OPK
Opko Health Inc.
stockNASDAQ
opko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.63 | 2026-10-22 | +0.88% | -0.338 |
| 1M | 1.62 | 2026-09-29 | +1.50% | 0.393 |
| 3M | 1.37 | 2026-07-29 | +20.46% | 0.395 |
| 6M | 1.11 | 2026-04-29 | +48.13% | 0.771 |
| 1Y | 1.43 | 2025-10-29 | +14.99% | 0.888 |
| 2Y | 1.60 | 2024-10-29 | +2.77% | — |
| 5Y | 3.79 | 2021-10-29 | -56.62% | 1.209 |
Opko Health Inc. (NASDAQ:OPK) stock price today is $1.64, and today's volume is 1,193,300. OPK is up 1.500% today. The 30 day average volume is 4.43M. OPK market cap is $1.23B with 746.33M shares outstanding.